Birgit C. Schultes, EVP and Chief Scientific Officer at Intellia Therapeutics ($NTLA), sold shares on the open market twice in the last year for a total of nearly $79,000. Her most recent sale occurred on January 5, 2026. These NTLA insider sales rank 9,901st among over 11,678 individual insiders, well below the average sale value of $8.6 million across about 6.4 transactions per insider. She made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Intellia Therapeutics, Inc. | $NTLA | Schultes Birgit C | EVP, Chief Scientific Officer | A | Common Stock | 39200 | $0.00 | 137,733.0000 | 115,829,926 | 39.78% | 0.03% |
| March 1, 2026 | Intellia Therapeutics, Inc. | $NTLA | Schultes Birgit C | EVP, Chief Scientific Officer | A | Stock Option (right to buy) | 56000 | $0.00 | 56,000.0000 | 115,829,926 | 9999.99% | 0.05% |
| Jan. 5, 2026 | Intellia Therapeutics, Inc. | $NTLA | Schultes Birgit C | EVP, Chief Scientific Officer | S | Common Stock | 8508 | $9.21 | 98,533.0000 | 115,829,926 | 7.95% | 0.01% |
| Oct. 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Schultes Birgit C | EVP, Chief Scientific Officer | S | Common Stock | 31 | $17.38 | 105,184.0000 | 103,517,460 | 0.03% | 0.00% |
| March 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Schultes Birgit C | EVP, Chief Scientific Officer | A | Common Stock | 37600 | $0.00 | 105,215.0000 | 103,517,460 | 55.61% | 0.04% |
| March 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Schultes Birgit C | EVP, Chief Scientific Officer | A | Stock Option (right to buy) | 53714 | $0.00 | 53,714.0000 | 103,517,460 | 9999.99% | 0.05% |